RNA
Income statement / Annual
Last year (2023), Avidity Biosciences, Inc.'s total revenue was $9.56 M,
an increase of 3.64% from the previous year.
In 2023, Avidity Biosciences, Inc.'s net income was -$212.22 M.
See Avidity Biosciences, Inc.,s key income statements, including revenue, expenses, profit, and income.
Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
Operating Revenue |
$9.56 M
|
$9.22 M
|
$9.33 M
|
$6.79 M
|
$2.32 M
|
$379,000.00
|
Cost of Revenue |
$2.10 M |
$1.39 M |
$639,000.00 |
$37.60 M |
$14.54 M |
$8.44 M |
Gross Profit |
$7.46 M |
$7.84 M |
$8.69 M |
-$30.82 M |
-$12.22 M |
-$8.06 M |
Gross Profit Ratio |
0.78 |
0.85 |
0.93 |
-4.54 |
-5.27 |
-21.26 |
Research and Development
Expenses |
$190.97 M
|
$150.40 M
|
$101.18 M
|
$37.60 M
|
$14.54 M
|
$8.44 M
|
General & Administrative
Expenses |
$54.19 M
|
$37.73 M
|
$26.20 M
|
$13.46 M
|
$5.11 M
|
$2.44 M
|
Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Selling, General &
Administrative Expenses |
$54.19 M
|
$37.73 M
|
$26.20 M
|
$13.46 M
|
$5.11 M
|
$2.44 M
|
Other Expenses |
$0.00 |
$4.92 M |
$42,000.00 |
-$78,000.00 |
$0.00 |
$0.00 |
Operating Expenses |
$245.16 M |
$188.14 M |
$127.38 M |
$51.06 M |
$19.65 M |
$10.88 M |
Cost And Expenses |
$245.16 M |
$188.14 M |
$127.38 M |
$51.06 M |
$19.65 M |
$10.88 M |
Interest Income |
$23.97 M |
$4.98 M |
$104,000.00 |
$206,000.00 |
$7.39 M |
$0.00 |
Interest Expense |
$0.00 |
$0.00 |
$0.00 |
$209,000.00 |
$7.39 M |
$718,000.00 |
Depreciation &
Amortization |
$2.10 M
|
$1.39 M
|
$639,000.00
|
$373,000.00
|
$597,000.00
|
$383,000.00
|
EBITDA |
-$233.50 M
|
-$177.53 M
|
-$117.41 M
|
-$43.77 M
|
-$16.75 M
|
-$10.12 M
|
EBITDA Ratio |
-24.42 |
-19.4 |
-12.66 |
-6.52 |
-7.32 |
-26.69 |
Operating Income Ratio
|
-24.64
|
-19.4
|
-12.66
|
-6.52
|
-7.47
|
-27.7
|
Total Other
Income/Expenses Net |
$23.38 M
|
$4.92 M
|
$42,000.00
|
-$78,000.00
|
-$7.40 M
|
-$718,000.00
|
Income Before Tax |
-$212.22 M |
-$174.00 M |
-$118.01 M |
-$44.36 M |
-$24.73 M |
-$11.22 M |
Income Before Tax Ratio
|
-22.2
|
-18.86
|
-12.65
|
-6.54
|
-10.67
|
-29.59
|
Income Tax Expense |
$0.00 |
-$4.92 M |
-$639,000.00 |
-$373,000.00 |
$7.39 M |
$718,000.00 |
Net Income |
-$212.22 M |
-$169.08 M |
-$117.37 M |
-$43.98 M |
-$32.12 M |
-$11.93 M |
Net Income Ratio |
-22.2 |
-18.33 |
-12.59 |
-6.48 |
-13.85 |
-31.49 |
EPS |
-2.91 |
-3.24 |
-2.83 |
-2.03 |
-0.86 |
-0.58 |
EPS Diluted |
-2.91 |
-3.24 |
-2.83 |
-2.03 |
-0.86 |
-0.58 |
Weighted Average Shares
Out |
$73.01 M
|
$52.16 M
|
$41.43 M
|
$21.66 M
|
$37.51 M
|
$20.68 M
|
Weighted Average Shares
Out Diluted |
$73.01 M
|
$52.16 M
|
$41.43 M
|
$21.66 M
|
$37.51 M
|
$20.68 M
|
Link |
|
|
|
|
|
|